Trial Profile
A global, proof-of-concept phase II trial of HMPL-523 in lupus-erythematosus
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2017
Price :
$35
*
At a glance
- Drugs Sovleplenib (Primary)
- Indications Systemic lupus erythematosus
- Focus Proof of concept; Therapeutic Use
- 10 Jan 2017 According to a Chi-Med media release, company expects to initiate this study in 2017.
- 05 Nov 2015 New trial record